Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus HYDRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus HYDRAMINE.
DECABID vs HYDRAMINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Antagonist of histamine H1 receptors, preventing histamine-mediated responses such as vasodilation, bronchoconstriction, and increased capillary permeability.
Relief of symptoms associated with seasonal or perennial allergic rhinitisRelief of nasal congestionRelief of sneezing, rhinorrhea, and itchy/watery eyes
Allergic rhinitisUrticariaMotion sicknessNausea and vomiting
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
50-100 mg IV/IM every 4-6 hours, maximum 400 mg per day. Also available as 50 mg oral tablets.
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life 5.7 hours, range 4.2-7.7 hours; prolonged in hepatic impairment (up to 15 hours in cirrhosis)
Chlorpheniramine is extensively metabolized in the liver via N-demethylation (CYP2D6, CYP3A4) to inactive metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation to active metabolite, but mainly excreted unchanged in urine.
Hepatic via CYP450 enzymes (primarily CYP2D6 and CYP3A4); metabolites include diphenhydramine and norfluoxetine.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Primarily renal (95%) as metabolites; <5% unchanged; 5% fecal
95% bound to albumin and alpha-1 acid glycoprotein
75-85% bound to albumin, α1-acid glycoprotein, and lipoproteins
0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution
6.5-8 L/kg (0.8-1.2 L/kg in neonates); extensive tissue distribution, crosses blood-brain barrier
Oral: 70% (first-pass metabolism reduces absorption); IM: 90%
Oral: 40-60% due to extensive first-pass metabolism; sublingual: not available; intramuscular: 80-100%
No specific guidelines; contraindicated in severe renal impairment (CrCl <30 mL/min).
CrCl 10-50 mL/min: administer every 6-8 hours; CrCl <10 mL/min: administer every 8-12 hours.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C).
Child-Pugh Class B or C: reduce dose by 50% or extend dosing interval to every 8-12 hours.
Not recommended for children under 6 years; for ages 6-12: 0.5 capsule (5 mg phenylephrine/37.5 mg carbinoxamine) every 12 hours.
1.25 mg/kg IV/IM every 6 hours (maximum single dose 50 mg). Oral: 5 mg/kg/day divided every 6 hours.
Use with caution; increased sensitivity to anticholinergic effects and hypertension; consider lower starting dose.
Start at 25 mg every 6-8 hours; increase cautiously due to increased risk of anticholinergic effects and confusion.
No FDA black box warnings.
None.
["Use caution in patients with hypertension, heart disease, hyperthyroidism, diabetes, or prostate enlargement","May cause drowsiness; avoid driving or operating machinery","Avoid concurrent use with MAO inhibitors or other sympathomimetics","Use in elderly may cause increased sensitivity to anticholinergic effects"]
May cause drowsiness; avoid driving or operating machinery. Use with caution in patients with asthma, glaucoma, prostatic hyperplasia, or hepatic impairment. Elderly patients more sensitive to anticholinergic effects.
["Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component","Severe hypertension or coronary artery disease","Concurrent use of MAO inhibitors or within 14 days of discontinuation","Angle-closure glaucoma","Urinary retention","Children under 6 years of age (due to risk of adverse effects)"]
Hypersensitivity to hydramine or its components. Concurrent use with MAOIs. Severe liver disease. Neonates and premature infants. Nursing mothers.
Data Pending Review
Data Pending Review
Avoid excessive consumption of caffeinated beverages, as Decabid may potentiate CNS stimulation. No specific food restrictions; maintain consistent sodium intake to reduce blood pressure fluctuations.
No significant food interactions; alcohol should be avoided due to additive CNS depression.
Decabid (debrisoquine) is not assigned an FDA pregnancy category. Animal studies have not been conducted; no human data are available. First trimester: potential risk cannot be ruled out. Second and third trimesters: unknown risk; avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No adequate studies in humans; animal studies have shown teratogenic effects at high doses. Avoid use unless benefit outweighs risk. Second and third trimesters: No specific fetal risks reported, but anticholinergic effects may cause fetal tachycardia or meconium ileus. Use with caution.
No data on excretion into breast milk. M/P ratio unknown. Use caution; monitor infant for hypotension and bradycardia. Consider alternative agents.
Not recommended during breastfeeding. No data on M/P ratio; antihistamines may be excreted into breast milk and could cause irritability or drowsiness in infants. Consider alternatives.
No specific pharmacokinetic studies in pregnancy. Reduced plasma protein binding and increased clearance may occur; consider dose adjustment based on clinical response. Start at lowest effective dose and titrate cautiously.
No specific pharmacokinetic data available for pregnancy. Use lowest effective dose for shortest duration. Dose adjustments not typically required, but monitor for increased clearance in later pregnancy.
Category C
Category C
Decabid (indoramin) is an alpha-1 adrenergic antagonist used for hypertension. Monitor for orthostatic hypotension, especially at initiation or dose increase. May cause sedation; avoid concurrent CNS depressants. Use with caution in patients with hepatic impairment or history of depression. Tachyphylaxis may occur with prolonged use.
Hydramine (diphenhydramine) is a first-generation antihistamine with strong anticholinergic effects. Use with caution in elderly due to increased risk of confusion, falls, and urinary retention. Avoid in patients with narrow-angle glaucoma, prostatic hypertrophy, or during acute asthma attacks. Sedative effects can be utilized for sleep but tolerance develops quickly; not recommended for chronic insomnia.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.Rise slowly from sitting or lying to avoid dizziness or fainting from low blood pressure.Avoid driving or operating machinery until you know how this drug affects you; it may cause drowsiness.Do not drink alcohol or use other sedatives while taking this medication.Report persistent dizziness, fainting, or unusual tiredness to your healthcare provider.
Take exactly as prescribed; do not exceed recommended dose.This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.Avoid alcohol and other CNS depressants while taking this drug.Do not use for longer than recommended for sleep; tolerance may develop.Report any vision changes, difficulty urinating, or rapid heartbeat to your healthcare provider.Store at room temperature away from moisture and heat.Keep out of reach of children; overdose may be fatal.